These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34383318)

  • 1. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
    Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
    J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
    Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
    Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
    Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
    Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
    Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
    Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
    T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K
    AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
    Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of tramadol and
    Lee J; Yoo HD; Bae JW; Lee S; Shin KH
    Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration.
    Porażka J; Szałek E; Połom W; Czajkowski M; Grabowski T; Matuszewski M; Grześkowiak E
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):579-584. PubMed ID: 30778911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.
    Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Brosen K
    Clin Pharmacol Ther; 2009 Dec; 86(6):626-33. PubMed ID: 19710642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
    Srinivas NR
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
    Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
    Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin markedly decreases the exposure to oral and intravenous tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Neuvonen M; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1293-301. PubMed ID: 23242004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
    Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
    Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
    Salman S; Sy SK; Ilett KF; Page-Sharp M; Paech MJ
    Eur J Clin Pharmacol; 2011 Sep; 67(9):899-908. PubMed ID: 21394525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.